|By PR Newswire||
|February 4, 2014 07:01 PM EST||
DUBLIN, February 5, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/vgwhc9/new_oral) has announced the addition of the "Concise Analysis of the International New Oral Anticoagulants Markets" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Anticoagulants decrease the ability of the blood to create harmful blood clots that can ultimately leading to a heart attack or stroke. Although sometimes referred to as blood thinners, they do not actually thin the blood and only help prevent the formation of new blood clots. For more than 50 years and until recently, the only oral anticoagulants were vitamin K antagonists such as warfarin. Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban) and other new oral anticoagulants have several advantages over warfarin, including no periodical laboratory monitoring and more predictable effects with fixed doses.
This report provides a thorough overview of these and other new oral anticoagulants, their approved indications, drug profiles, pharmacokinetic parameters and the respective areas of market growth. The study also analyzes almost all of the companies known to be marketing, manufacturing or developing oral anticoagulant products in the U.S. and worldwide. Detailed tables and charts with sales forecasts and marketshare data are also included.
Key Topics Covered:
2. An Overview of Anticoagulants
3. Selected Oral Anticoagulants
4. A Brief Overview of Antiplatelets
5. Coagulation Assays
6. Disease Conditions Targeted by Anticoagulants
7. Market Analysis: Anticoagulants
8. Market for Antiplatelets
9. Deals in Anti-Thrombotic Therapeutics Sector
10. Utilization of Anticoagulants and Antiplatelets in the U.S.
11. Selected Company Profiles
- 1 Varespladib/A-002
- Activase (Altepase)
- Akers Biosciences, Inc.
- Angiomax (Bivalirudin)
- Anthera Pharmaceuticals, Inc.
- AstraZeneca, PLC
- Boehringer Ingelheim GmbH
- Boehringer's Dedication to Innovation
- Boehringer's Therapeutic Breakthrough
- Brilinta (Ticagrelor)
- Cipla Limited
- Clinical Studies
- Coronary Artery By-Pass Graft Surgery-Related Bleeding
- Daiichi Sankyo Company Ltd.
- Discontinuation of Effient
- Effient (Daiichi Sankyo)
- Eisai Co., Ltd.
- Eli Lilly & Co
- Eliquis (Apixaban)
- Genentech, Inc.
- General Risk of Bleeding
- GlaxoSmithKline PLC
- Hypersensitivity Including Angiodema
- Lovenox (Enoxaparin)
- Medicure, Inc.
- Merck & Co., Inc.
- Novartis AG
- Ortho-McNeil Pharmaceutical, Inc.
- PIFA Heparin/Platelet Factor 4 Rapid Assay
- Pfizer, Inc.
- Pharmion, LLC
- Portola Pharmaceuticals, Inc.
- RYx Therapeutics, Inc.
- Registration Study RE-LY
- Rivaroxaban (Xarelto)
- SCH 5303348
- Tecarfarin Development Status
- The Medicines Company
- Thrombotic Thrombocytopenic Purpura
- Tinzaparin (Innohep)
For more information visit http://www.researchandmarkets.com/research/vgwhc9/new_oral
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 27, 2016 02:00 AM EDT Reads: 1,709
Jul. 27, 2016 12:00 AM EDT Reads: 1,936
Jul. 27, 2016 12:00 AM EDT Reads: 1,997
Jul. 26, 2016 11:30 PM EDT Reads: 1,734
Jul. 26, 2016 11:00 PM EDT Reads: 2,574
Jul. 26, 2016 11:00 PM EDT Reads: 2,001
Jul. 26, 2016 10:45 PM EDT Reads: 1,093
Jul. 26, 2016 10:45 PM EDT Reads: 1,362
Jul. 26, 2016 10:30 PM EDT Reads: 1,363
Jul. 26, 2016 10:15 PM EDT Reads: 1,983
Jul. 26, 2016 09:00 PM EDT Reads: 2,038
Jul. 26, 2016 08:30 PM EDT Reads: 2,135
Jul. 26, 2016 08:00 PM EDT Reads: 331
Big Data engines are powering a lot of service businesses right now. Data is collected from users from wearable technologies, web behaviors, purchase behavior as well as several arbitrary data points we’d never think of. The demand for faster and bigger engines to crunch and serve up the data to services is growing exponentially. You see a LOT of correlation between “Cloud” and “Big Data” but on Big Data and “Hybrid,” where hybrid hosting is the sanest approach to the Big Data Infrastructure pro...
Jul. 26, 2016 07:15 PM EDT Reads: 1,932
In his session at 18th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., and Logan Best, Infrastructure & Network Engineer at Webair, focused on real world deployments of DDoS mitigation strategies in every layer of the network. He gave an overview of methods to prevent these attacks and best practices on how to provide protection in complex cloud platforms. He also outlined what we have found in our experience managing and running thousands of Linux and Unix ...
Jul. 26, 2016 07:00 PM EDT Reads: 1,801